Lupus nephritis: A 15-year multi-centre experience in the UK

Lupus

Volumn 22, Issue 3, 2013, Pages 328-332

  Hui, M ^a,b,c   Garner, R ^a   Rees, F ^b   Bavakunji, R ^a   Daniel, P ^c   Varughese, S ^c   Srikanth, A ^a   Andres, M ^a   Pearce, F ^a   Leung, J ^b   Lim, K ^c   Regan, M ^b   Lanyon, P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

lupus nephritis; nephritis; renal lupus; SLE; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GREAT BRITAIN; HUMANS; LUPUS NEPHRITIS; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84874442319     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312474084     Document Type: Review

References (11)

1. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010 ; 69: 1269-1274
2. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 ; 46: 2121-2131
3. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
4. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432.
5. Proteinuria. The National Kidney Federation. 27-2-2011. http://www.kidney.org.uk/Medical-Info/kidney-disease/proturia.html.
6. Wahbeh AM, Ewais MH, Elsharif ME. Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria. Saudi J Kidney Dis Transpl. 2009 ; 20: 443-447
7. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002 ; 46: 995-1002
8. Sidiropoulos PI, Kritikos HD, Boumpas DT Lupus nephritis flares. Lupus 14: 49-52.
9. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology (Oxford). 2010 ; 49: 128-140
10. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010 ; 69: 2083-2089
11. Houssiau FA. (Personal Communication) European Lupus Meeting - Meet the Professor. 07.04.2011. http://www.lupus2011.org/nm-quemsomos13f1.html?id=200.